Compare TSEM & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSEM | RMD |
|---|---|---|
| Founded | 1993 | 1989 |
| Country | Israel | United States |
| Employees | N/A | 10600 |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 28.4B |
| IPO Year | 1996 | N/A |
| Metric | TSEM | RMD |
|---|---|---|
| Price | $257.98 | $191.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $161.75 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.21 | $10.60 |
| Revenue Next Year | $26.62 | $7.41 |
| P/E Ratio | $66.16 | ★ $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.12 | $180.27 |
| 52 Week High | $319.94 | $293.81 |
| Indicator | TSEM | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 41.72 |
| Support Level | $198.24 | $190.25 |
| Resistance Level | $278.73 | $197.41 |
| Average True Range (ATR) | 15.92 | 5.86 |
| MACD | 2.07 | -1.32 |
| Stochastic Oscillator | 67.24 | 2.98 |
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs) based on the design specifications of customers. The company's line of integrated circuits is incorporated into markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.